Affiliations and Referenses https://link.springer.com/article/10.3103/S0095452723020044
REFERENCES
Siegel, R.L., Miller, K.D., and Jemal, A., Cancer statistics, Ca-Cancer J. Clin., 2016, vol. 66, no. 1, pp. 7–30.
Smith, R.A., Andrews, K.S., Brooks, D., Fedewa, S.A., Manassaram-Baptiste, D, Saslow, D., et al., Cancer screening in the United States, A review of current American Cancer Society guidelines and current issues in cancer screening, Ca-Cancer J. Clin., 2018, vol. 68, no. 4, pp. 297–316.
Siegel, R., DeSantis, C., Virgo, K., Stein, K., Mariotto, A., Smith, T., et al., Cancer treatment and survivorship statistics, Ca-Cancer J. Clin., 2012, vol. 62, no. 4, pp. 220−241.
Basu, A. and Krishnamurthy, S., Cellular responses to Cisplatin-induced DNA damage, J. Nucleic Acids, 2010, p. 2010.
Florea, A.-M. and Busselberg, D., Cisplatin as an anti-tumor drug: Cellular mechanisms of activity, drug resistance and induced side effects, Cancers, 2011, vol. 3, no. 1, pp. 1351–1371.
Galluzzi, L., Senovilla, L., Vitale, I., Michels, J., Martins, I., Kepp, O., et al., Molecular mechanisms of cisplatin resistance, Oncogene, 2012, vol. 31, no. 15, p. 1869.
Nematbakhsh, M., Ashrafi, F., Pezeshki, Z., Fatahi, Z., Kianpoor, F., Sanei M.-H., et al., A histopathological study of nephrotoxicity, hepatoxicity or testicular toxicity: Which one is the first observation as side effect of Cisplatin-induced toxicity in animal model?, J. Nephropathol.,2 2012, vol. 1, no. 3, p. 190.
Vanitha, M., Baskaran, K., Periyasamy, K., Saravanan, D., Ilakkia, A., Selvaraj, S., et al., A review on the biomedical importance of taurine, Int. J. Pharm. Res. Health Sci., 2015, vol. 3, no. 3, pp. 680–686.
El Agouza, I., Eissa, S., El Houseini, M., El-Nashar, D.E., and El Hameed, O.A., Taurine: A novel tumor marker for enhanced detection of breast cancer among female patients, Angiogenesis, 2011, vol. 14, no. 3, p. 321.
Zhang, X., Tu, S., Wang, Y., Xu, B., and Wan, F., Mechanism of taurine-induced apoptosis in human colon cancer cells, Acta Biochim. Biophys. Sin., 2014, vol. 46, no. 4, pp. 261–272.
Zhang, X., Lu, H., Wang, Y., Liu, C., Zhu, W., Zheng, S., et al., Taurine induces the apoptosis of breast cancer cells by regulating apoptosis-related proteins of mitochondria, Int. J. Mol. Med., 2015, vol. 35, no. 1, pp. 218–226.
Sato, S., Yamate, J., Saito, T., Hosokawa, T., Saito, S., and Kurasaki, M., Protective effect of taurine against renal interstitial fibrosis of rats induced by cisplatin, Naunyn-Schmiedeberg’s Arch. Pharmacol., 2002, vol. 365, no. 4, pp. 277–283.
Chowdhury, S., Sinha, K., Banerjee, S., and Sil, P.C., Taurine protects cisplatin induced cardiotoxicity by modulating inflammatory and endoplasmic reticulum stress responses, Biofactors, 2016, vol. 42, no. 6, pp. 647–664.
Zafari, J., Vazini, H., Javani-jouni, F., Abdolmaleki, P., Monajemi, R., Shams, E., et al., Anticancer Effects of Moderate Static Magnetic Field on Cancer Cells In Vitro, Res. Mol. Med., 2018, vol. 6, no. 3, pp. 54–64.
Miller, K.D., Siegel, R.L., Lin, C.C., Mariotto, A.B., Kramer, J.L., Rowland, J.H., et al., Cancer treatment and survivorship statistics, Ca-Cancer J. Clin., 2016, vol. 66, no. 4, pp. 271–289.
Tu, S., Zhang, X.L., Wan, H.F., Xia, Y.Q., Liu, Z.Q., Yang, X.H., et al., Effect of taurine on cell proliferation and apoptosis human lung cancer A549 cells, Oncol. Lett., 2018, vol. 15, no. 4, pp. 5473–5480.
Arnesano, F., Losacco, M., and Natile, G., An updated view of cisplatin transport, Eur. J. Inorg. Chem., 2013, vol. 2013, no. 15, pp. 2701–2711.
Kim, C.W., Lu, J.N., Go, S.-I., Jung, J.H., Yi, S.M., Jeong, J.-H., et al., p53 restoration can overcome cisplatin resistance through inhibition of Akt as well as induction of Bax, Int. J. Oncol., 2013, vol. 43, no. 5, pp. 1495–1502.
Chen, D., Milacic, V., Frezza, M., and Dou, Q.P., Metal complexes, their cellular targets and potential for cancer therapy, Curr. Pharm. Des., 2009, vol. 15, no. 7, pp. 777–791.
Jalali, A., Zafari, J., Jouni, F.J., Abdolmaleki, P., Shirazi, F.H., and Khodayar, MJJIjorb, Combination of Static Magnetic Field and Cisplatin in Order to Reduce Drug Resistance in Cancer Cell Lines, 2019, pp. 1–8.
Vasan, N., Baselga, J., and Hyman, D.M., A view on drug resistance in cancer, Nature, 2019, vol. 575, no. 7782, pp. 299–309.
Beretta, G.L., Gatti, L., Tinelli, S., Corna, E., Colangelo, D., Zunino, F., et al., Cellular pharmacology of cisplatin in relation to the expression of human copper transporter CTR1 in different pairs of cisplatin-sensitive and-resistant cells, Biochem. Pharmacol., 2004, vol. 68, no. 2, pp. 283–291.
Holzer, A.K., Katano, K., Klomp, L.W., and Howell, S.B., Cisplatin rapidly down-regulates its own influx transporter hCTR1 in cultured human ovarian carcinoma cells, Clin. Cancer Res., 2004, vol. 10, no. 19, pp. 6744–6749.
Safaei, R. and Howell, S.B., Copper transporters regulate the cellular pharmacology and sensitivity to Pt drugs, Crit. Rev. Oncol./Hematol., 2005, vol. 53, no. 1, pp. 13–23.
Tsai, C.-Y., Larson, C.A., Safaei, R., and Howell, S.B., Molecular modulation of the copper and cisplatin transport function of CTR1 and its interaction with IRS-4, Biochem. Pharmacol., 2014, vol. 90, no. 4, pp. 379–387.
Saad, S.Y. and Al-Rikabi, A.C., Protection effects of taurine supplementation against cisplatin-induced nephrotoxicity in rats, Chemotherapy, 2002, vol. 48, no. 1, pp. 42–48.
Kim, T. and Kim, A.K., Taurine enhances anticancer activity of cisplatin in human cervical cancer cells, Taurine 8, Springer, 2013, pp. 189–198.
Author information
Authors and Affiliations
Corresponding author
About this article
Cite this article
Jouni, F.J., Zafari, J., Abbasifard, M. et al. Erratum to: Synergistic Effects on Taurine and Cisplatin on Lung Cancer Cells (A549). Cytol. Genet. 57, 384–385 (2023). https://doi.org/10.3103/S0095452723040047
Published:
Issue Date:
DOI: https://doi.org/10.3103/S0095452723040047